文献速递泌尿生殖与妇科肿瘤放疗

高危前列腺癌ADT与外照射放疗启动时机的影响

Influence of Timing Between Androgen Deprivation Therapy and External Beam Radiation Therapy in Patients With Localized, High-Risk Prostate Cancer.
PubMed 文献 · Adv Radiat Oncol · 2021-09-10

该研究基于美国国家癌症数据库(2004-2015),纳入37,606例接受根治性外照射放疗(≥60 Gy)且ADT在放疗前或放疗开始后14天内启动的高危前列腺癌患者,按ADT启动时间分组比较总生存。中位随访68.9个月,ADT在放疗前8至11周启动组总生存显著优于更短疗程组(校正HR 0.90,95%CI 0.86-0.95,P<.001),而>11周组无此优势。

要点

  • ADT于放疗前8至11周启动与总生存改善显著相关(校正HR 0.90)。
  • >11周组未显示总生存优势。
  • 未校正10年OS:>11周49.9%、8至11周51.2%、<8周46.9%(P=.002)。

核心结论

  • 在高危前列腺癌中,ADT于放疗前8至11周启动与更短新辅助ADT疗程相比与总生存显著改善相关,而>11周组未见此优势。

研究设计与样本

  • 回顾性队列研究,数据来自美国国家癌症数据库(2004-2015)。
  • 纳入临床T1-T4 N0 M0、NCCN高危前列腺癌、接受根治性外照射放疗(≥60 Gy)且ADT在放疗前或放疗开始后14天内启动的患者,共37,606例。
  • 按ADT启动时间分组:>11周前、8至11周前、<8周前;采用Kaplan-Meier、倾向评分匹配和多变量Cox比例风险模型评估总生存。

主要发现

  • 中位随访68.9个月;>11周组13,346例(35.5%),8至11周组11,456例(30.5%),<8周组12,804例(34%)。
  • 未校正10年OS率分别为>11周49.9%、8至11周51.2%、<8周46.9%(P=.002)。
  • 多变量及逆概率治疗加权分析显示8至11周组总生存显著获益(校正HR 0.90;95%CI 0.86-0.95;P<.001),>11周组无显著获益。

关键数值与推荐

  • ADT启动时间分组界值:>11周、8至11周、<8周(相对放疗开始)。
  • 放疗剂量条件:根治性外照射≥60 Gy。
  • 8至11周组校正HR 0.90(95%CI 0.86-0.95,P<.001);未校正10年OS率49.9%、51.2%、46.9%(P=.002)。

临床怎么用

  • 对接受根治性外照射放疗的高危前列腺癌患者,可考虑在放疗前8至11周启动ADT。
  • 该结果属回顾性证据,需前瞻性验证后再用于常规时机决策。

局限性

  • 为回顾性数据库分析,存在选择偏倚等混杂可能。
  • 作者指出需要前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Treatment with long-term androgen deprivation therapy (ADT) and radiation therapy (RT) is the nonsurgical standard-of-care for patients with high- or very high-risk prostate cancer (HR-PC), but the optimal timing between ADT and RT initiation is unknown. We evaluate the influence of timing between ADT and RT on outcomes in patients with HR-PC using a large national cancer database. METHODS AND MATERIALS: Data for patients with clinical T1-T4 N0, M0, National Cancer Comprehensive Network HR-PC who were treated with definitive external RT (≥60 Gy) and ADT starting either before or within 14 days after RT start were extracted from the National Cancer Database (2004-2015). Patients were grouped on the basis of ADT initiation: (1) >11 weeks before RT, (2) 8 to 11weeks before RT, and (3) <8 weeks before RT. Kaplan-Meier, propensity score matching, and multivariable Cox proportional hazards were performed to evaluate overall survival (OS). RESULTS: With a median follow-up of 68.9 months, 37,606 patients with HR-PC were eligible for analysis: 13,346 (35.5%) with >11 weeks of neoadjuvant ADT, 11,456 (30.5%) with 8 to 11 weeks of neoadjuvant ADT; and 12,804 (34%) patients with <8 weeks of neoadjuvant ADT. The unadjusted 10-year OS rates for >11 weeks, 8 to 11 weeks, and <8 weeks neoadjuvant ADT groups were 49.9%, 51.2%, and 46.9%, respectively (P = .002). On multivariable and inverse probability of treatment weighting analyses, there was a significant OS advantage for patients in the 8 to 11 weeks neoadjuvant ADT group (adjusted hazard ratio 0.90; 95% confidence interval, 0.86-0.95; P < .001) but not the >11 weeks group. CONCLUSIONS: Neoadjuvant ADT initiation 8 to 11 weeks before RT is associated with significantly improved OS compared with shorter neoadjuvant ADT duration. Although prospective validation is warranted, this analysis is the largest retrospective study suggesting an influence of timing between ADT and RT initiation in HR-PC.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. McCall NS, Liu Y, Patel SA, et al. Influence of Timing Between Androgen Deprivation Therapy and External Beam Radiation Therapy in Patients With Localized, High-Risk Prostate Cancer. Adv Radiat Oncol. 2021. PMID: 34703954. doi:10.1016/j.adro.2021.100803

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。